listeo-data-scraper domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/healingmaps.imarkdev.com/wp-includes/functions.php on line 6170
The first call rarely announces itself as an offer. It sounds like a compliment, someone building a platform in your region admires what you have built and wonders whether you have ever thought about partners. What happens next depends almost entirely on work you either did or did not do during the two years before […]
Read More
Ketamine clinics often pair medication with therapy, preparation, or integration. A new review asks whether psychotherapy adds measurable benefit for adults with depression. The answer remains uncertain. Researchers found widespread clinical use, but far less rigorous evidence than the popularity of these programs may suggest. New: Interested in Being Part of a Psychedelics-Focused Clinical Trial? Sign […]
Read More
On July 16, Eli Lilly agreed to pay up to $3.8 billion for AtaiBeckley and its late stage psychedelic depression program. A week earlier, Johnson & Johnson reported $584 million in quarterly Spravato sales, up 40 percent in a year. AbbVie has already committed up to $1.2 billion for a psychedelic depression drug from Gilgamesh. […]
Read More
The national median price of a ketamine infusion in 2026 is $400. That number comes from our own directory. We reviewed all 1,793 ketamine clinic listings on HealingMaps in July 2026, identified every clinic that publicly posts a treatment price, and verified 91 standard per session prices across 30 states. No survey, no estimates, no […]
Read More
A study reports symptom improvement among patients in Mindbloom’s at-home ketamine injections. However, this was not an independent test.
Read More
Ketamine can reduce pain while producing an altered sense of self. A new study suggests they may travel along separate biological paths.
Read More
Eli Lilly, the world’s largest pharmaceutical company, confirmed Thursday morning that it will acquire AtaiBeckley in a deal worth up to $3.8 billion. The purchase hands Lilly the company’s lead candidate, an intranasal form of 5-MeO-DMT for treatment resistant depression that is now entering Phase 3 trials. No acquisition in psychedelic medicine has come close […]
Read More
The FDA's new guidance is the clearest signal yet that a new category of treatment is about to arrive. Ketamine clinics are the infrastructure best positioned to deliver it.
Read More
The FDA finalized its first formal guidance for studying psychedelic drugs. The document sets the ground rules for research into psilocybin, LSD, and MDMA.
Read More
The Texas Medical Board rewrote its proposed ketamine rules. The July 10 version is out. Here's what Texas clinics should do now.
Read More